Coya Therapeutics, Inc. (NASDAQ:COYA) Insider Fred Grossman Purchases 2,710 Shares

Coya Therapeutics, Inc. (NASDAQ:COYA) insider Fred Grossman bought 2,710 shares of the stock in a transaction on Monday, November 11th. The shares were acquired at an average cost of $7.37 per share, for a total transaction of $19,972.70. Following the completion of the transaction, the insider now directly owns 2,710 shares of the company’s stock, valued at approximately $19,972.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Coya Therapeutics Stock Down 1.1 %

Shares of COYA opened at $7.25 on Wednesday. The firm’s fifty day simple moving average is $7.07 and its two-hundred day simple moving average is $7.01. Coya Therapeutics, Inc. has a 12 month low of $4.75 and a 12 month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. On average, equities research analysts predict that Coya Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently bought and sold shares of COYA. Vanguard Group Inc. increased its position in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the third quarter valued at $169,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics during the second quarter valued at about $101,000. Finally, Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics in the second quarter worth about $61,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

COYA has been the subject of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.